Skip to main content


Page 147 of 147

  1. Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given diff...

    Authors: Michael H Alderman

    Citation: Trials 2000 1:69

    Content type: Commentary

    Published on:

  2. Direct myocardial cell protection in patients with unstable angina or evolving myocardial infarction (MI) could prevent cell necrosis or reduce its extent, and minimize the risk of MI and death associated with...

    Authors: Pierre Theroux, Bernard R Chaitman, Leif Erhardt, Andreas Jessel, Thomas Meinertz, Wolf-Ulrich Nickel, John S Schroeder, Gianni Tognoni, Harvey White and James T Willerson

    Citation: Trials 2000 1:59

    Content type: Research

    Published on:

  3. The results of recent randomized trials to test the influence of antioxidants on coronary-event rates and prognosis in patients with coronary-artery disease were disappointing. In none of these studies did the...

    Authors: Ascan Warnholtz and Thomas Münzel

    Citation: Trials 2000 1:38

    Content type: Commentary

    Published on:

  4. The present review assesses the data on long-term outcome after coronary stenting. Histological, angiographical and intravascular imaging data have shown that the insertion of stents constitutes only a transie...

    Authors: Adnan Kastrati, Donald Hall and Albert Schömig

    Citation: Trials 2000 1:48

    Content type: Review

    Published on:

  5. Although the TIMI (Thrombolysis In Myocardial Infarction) flow grade classification scheme is widely used to assess angiographic outcomes, it is limited by poor reproducibility and its categoric nature. The co...

    Authors: Mark A Appleby, Andrew D Michaels, Michael Chen and C Gibson Michael

    Citation: Trials 2000 1:31

    Content type: Commentary

    Published on:

  6. This symposium provided a useful forum for the discussion of issues relating to the design and conduct of clinical trials. There is a need for greater awareness of the complexity of modern day trials, in which...

    Authors: Rachel N Johnatty

    Citation: Trials 2000 1:55

    Content type: Meeting report

    Published on:

  7. Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that...

    Authors: Steven M Snapinn

    Citation: Trials 2000 1:19

    Content type: Commentary

    Published on:

  8. The prognosis of patients who present with non-ST segment elevation acute coronary syndromes (ACS) is guarded. These patients can be risk-stratified on the basis of symptom complex, electrocardiographic ST seg...

    Authors: Dean J Kereiakes

    Citation: Trials 2000 1:9

    Content type: Commentary

    Published on:

Annual Journal Metrics